Close Menu

NEW YORK (GenomeWeb) – GenMark Diagnostics said Thursday that it has applied to the US Food and Drug Administration for clearance of its ePlex Blood Culture ID – Gram Positive (BCID-GP) panel.

It is the first of three blood culture panels being developed on the ePlex molecular sample-to-answer system for the diagnosis and management of bloodstream infections that can lead to sepsis, the firm said.

To read the full story....

...and receive Daily News bulletins.

Already have a 360Dx or GenomeWeb account?
Login Now.

Don't have a 360Dx or GenomeWeb account?
Register for Free.

Oct
09
Sponsored by
PerkinElmer

As cases of COVID-19 continued to grow this spring and summer in the US, so too did the number of Emergency Use Authorizations from the FDA for clinical diagnostic tests aimed at detecting current and past infections.